Clinical Trials

As part of the development process, our investigational radioligand products are evaluated in clinical trials to find new and better ways to image and treat disease. These studies are sponsored by Advanced Accelerator Applications (AAA).

Investigational products tested in clinical trials may not be approved by regulatory authorities, or they may be approved for certain indications but being tested to determine if they are useful in other conditions. Patients should discuss their potential participation in such studies with their physician. The table below lists ongoing oncology clinical trials with our investigational drugs.

Pre-Approval Access to AAA Products

As a Novartis Company, AAA is following the Novartis Position on Pre-Approval Access to Novartis Products through Novartis Managed Access Programs (MAPs).

If you need more information or want to submit a request for MAP, please visit the Novartis Managed Access Programs webpage.

Please Select Compound
Select Disease State
Study NumberStudy Name/TitlePhase
VISION: 177Lu-PSMA-617: Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer
NeoRay: [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB* Lesion Uptake.

*Formerly known as NeoBOMB1
Netter-2: Study to evaluate the efficacy and safety of Lutathera in patients with grade 2 and grade 3 advanced GEP-NET
Netter-1: Study comparing treatment with 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in patients with inoperable, progressive, somatostatin receptor positive midgut carcinoid tumors.

* Awaiting final analysis
NCT03490838 Eudra CT N°: 2017-004034-29
PROter: 177Lu-PSMA-R2 in patients with positive progressive, metastatic, castration resistant prostate cancer
PROfind: 68Ga-PSMA-R2 in patients with biochemical relapse and metastatic prostate cancer